@article{7481ecb8aa024af98a52b05440924634,
title = "Autoimmune GFAP astrocytopathy: Prospective evaluation of 90 patients in 1 year",
abstract = "In this prospective evaluation of serum and CSF samples, all but two CSF GFAPα-IgG positive patients had autoimmune meningoencephalomyelitis while serum GFAPα-IgG positivity alone was less specific. Phenotypes were diverse among patients that were serum positive only. Adult and pediatric clinical presentations were similar. Most patients were immunotherapy responsive. Co-existing NMDA-R-IgG and cancer were associated with lack of response to first-line immunotherapy. Among patients with follow-up information, 18% had relapses. This study demonstrates CSF GFAPα-IgG is a specific autoimmune meningoencephalomyelitis biomarker, with favorable corticosteroid response. Lack of response should prompt evaluation for co-existing NMDA-R-IgG or malignancy.",
keywords = "Autoimmune, Cerebrospinal fluid, Glial fibrillary astrocytic protein, Meningoencephalomyelitis, Pediatric",
author = "Divyanshu Dubey and Hinson, {Shannon R.} and Jolliffe, {Evan A.} and Anastasia Zekeridou and Flanagan, {Eoin P.} and Pittock, {Sean J.} and Eati Basal and Drubach, {Daniel A.} and Lachance, {Daniel H.} and Lennon, {Vanda A.} and Andrew McKeon",
note = "Funding Information: DD, SRH, EJ, AZ, EPF, EB, DD, DL report no disclosures. SP receives research support from and has consulted for Medimmune, Alexion and Grifols, but has not received any personal compensation. VL has a financial interest in the following intellectual property: “Marker for Neuromyelitis Optica.” A patent has been issued for this technology, and it has been licensed to commercial entities. She has received cumulative royalties of greater than the federal threshold for significant financial interest from the licensing of these technologies but receives no royalties from the sale of these tests by Mayo Medical Laboratories; however, Mayo Collaborative Services, Inc. does receive revenue for conducting these tests. AM receives research support from and has consulted for Euroimmun, Medimmune, and Grifols, but has not received personal compensation. Publisher Copyright: {\textcopyright} 2018 Elsevier B.V.",
year = "2018",
month = aug,
day = "15",
doi = "10.1016/j.jneuroim.2018.04.016",
language = "English (US)",
volume = "321",
pages = "157--163",
journal = "Journal of neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
}